Fractional Exhaled Nitric Oxide Measurements and Screening of Obstructive Sleep Apnea in a Sleep-Laboratory Setting: A Cross-Sectional Study

Ricardo L. M. Duarte1,2 · Marcelo F. Rabahi3 · Tiago S. Oliveira-e-Sá4,5 · Flavio J. Magalhães-da-Silveira1 · Fernanda C. Q. Mello2 · David Gozal6

Received: 16 October 2018 / Accepted: 16 December 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Purpose Obstructive sleep apnea (OSA) is a common condition characterized by repetitive collapse of the upper airways and intermittent oxygen desaturation, which may lead to airway inflammation. Here, we explored whether fractional exhaled nitric oxide (FeNO) levels provide a non-invasive screening tool of OSA.

Methods Over a 3-month period, FeNO levels were measured in consecutive non-smoking patients referred for a sleep laboratory. All patients underwent full polysomnography. OSA severity was classified based on the apnea/hypopnea index: ≥ 5.0/h as any OSA, ≥ 15.0/h as moderate/severe OSA, and ≥ 30.0/h as severe OSA. FeNO was measured by a portable device (NIOX-MINO®; Aerocrine AB, Solna, Sweden) and expressed as parts per billion (ppb). Discrimination by area under the curve (AUC) and binary logistic regression were performed.

Results A total of 229 subjects were evaluated. Mean FeNO values were similar among subjects without OSA or with OSA: 16.9 ± 10.6 ppb versus 20.2 ± 14.5 ppb, \( p = 0.221 \); respectively. FeNO was not an inclusionary parameter to predict any OSA, moderate/severe OSA, and severe OSA: odds ratio (OR) 1.023 (95% confidence interval [CI]: 0.986–1.062); OR 1.012 (95% CI: 0.991–1.034); and OR 0.999 (95% CI: 0.980–1.018), respectively. The AUC values for FeNO in the diagnosis of any OSA, moderate/severe OSA, and severe OSA showed no discriminatory properties: AUC: 0.567 (95% CI: 0.464–0.670), AUC: 0.541 (95% CI: 0.465–0.618), and AUC: 0.535 (95% CI: 0.459–0.610); respectively.

Conclusions In a sleep-lab setting, our findings suggest that FeNO measurements are inconsequential in the screening of OSA in adults.

Keywords Obstructive sleep apnea · Polysomnography · Fractional exhaled nitric oxide · Screening · Diagnosis

Introduction

Obstructive sleep apnea (OSA) is a highly prevalent disorder characterized by recurrent upper airway obstructive episodes, resulting in intermittent hypoxemia and arousals. The estimated prevalence of moderate-to-severe sleep-disordered breathing (SDB) ranges from 10 to 17% among men and from 3 to 9% among women [1], likely reflecting the increase in obesity rates and aging of the population [2, 3]. In certain risk groups, such as patients undergoing pre-operative evaluation for bariatric surgery [4] or resistant hypertension [5], the prevalence can reach more than 70%. In patients with OSA, the recurrent snoring and associated local mechanical trauma to the airway along with the recurrent upper airway collapse and intermittent hypoxia-re-oxygenation episodes
lead to release of inflammatory mediators, leading to both local upper airway and systemic inflammation [6].

Fractional exhaled nitric oxide (FeNO) can be easily, rapidly, and non-invasively measured for assessment of airway inflammation, and is extensively used in asthma to evaluate both severity and therapeutic responses [7–9]. However, FeNO levels in OSA patients remain somewhat unclear [10]: both elevated FeNO [11–15] and unaltered FeNO levels [16–19] have been reported when comparing OSA patients to controls. A recent meta-analysis [10] addressed FeNO levels in patients with OSA and concluded that there was a significant increase in FeNO levels in subjects diagnosed with OSA. Moreover, FeNO levels were significantly increased upon waking up in patients with OSA, but such pattern was not present in non-OSA groups. In addition, long-term continuous positive airway pressure (CPAP) significantly lowered FeNO levels in OSA patients. Notwithstanding the conclusions of the meta-analysis, some limitations are worthy of mention: (i) the available literature contains studies with a relatively small sample size; (ii) different techniques and instruments were used for FeNO measurements; (iii) substantial heterogeneity was present across the cohorts that were evaluated; and (iv) insufficient information regarding confounding factors, such as snoring or timing of FeNO measurement [10].

Here, we hypothesized that FeNO value is useful in the screening of OSA. Our major objectives in the context of FeNO measurements were (i) to verify if FeNO levels discriminate between patients with and without OSA and (ii) to evaluate whether FeNO levels can be used as a screening tool in patients with suspected OSA.

Methods

This cross-sectional study evaluated consecutive patients enrolled between January 2017 and March 2017, who were referred by their respective attending physicians. All studies were conducted in a single Brazilian center: Sleep Laboratory at Centro Medico BarraShopping, Rio de Janeiro. Inclusion criteria were subjects of both genders, aged ≥ 18 years with suspected SDB. Patients were excluded for any of the following reasons: current smokers, inhaled and/or systemic corticosteroids use, self-reported information of atopy or respiratory disease that might affect FeNO measurements (allergic rhinitis, asthma, and chronic obstructive pulmonary disease [COPD]), current respiratory tract infection, previously diagnosed OSA, and insufficient sleep or technically inadequate polysomnography (PSG). The study was approved by the Ethics Committee of the Federal University of Rio de Janeiro, Brazil (#1.764.165) and it was developed in accordance with the ethical standards laid down in the Declaration of Helsinki. All participants gave written informed consent prior any study procedure.

Patient characteristics included gender, race, age, body mass index (BMI), neck circumference (NC), and self-reported comorbidities (diabetes mellitus and hypertension). Patients were measured for weight and height, and BMI was calculated by dividing the weight in kilograms by the square of the height in meters (kg/m²), while NC was systematically measured, in centimeters, with a tape measure. All patients enrolled had complete data regarding the filling of two validated models: the Epworth Sleepiness Scale (ESS) [20] and the No-Apnea [21]. The ESS [20] is a questionnaire with eight questions related to the chance of dozing in daily situations, being its final score ranging from 0 to 24 points. Individuals with scores > 10 points are classified as having excessive daytime sleepiness [20]. The No-Apnea [21] is a newly developed and validated model, consisting of only two objective and easily measurable parameters: NC scored from 0 to 6 points and age scored from 0 to 3 points (final score ranging from 0 to 9 points). Subjects with scores ≥ 3 points are classified as high risk for OSA diagnosis [21].

FeNO Measurements

The measurements of FeNO were performed according to the recommendations proposed by the American Thoracic Society [7], always in the morning and immediately after the PSG, under the direction of an experienced technician. FeNO was measured by a portable device (NIOX-MINO®; Aerocrine AB, Solna, Sweden) and expressed as parts per billion (ppb). They were seated without a nose clip, inhaled to total lung capacity, and then exhaled at a constant flow rate of 50 mL/s as guided by an eye-level indicator for approximately 10 s. Two successive FeNO measurements were obtained and their mean values were recorded for analysis.

Sleep Test

All patients underwent an attended, in-laboratory PSG (EMBLA® S7000, Embla Systems, Inc., Broomfield, CO, USA), consisting of continuous monitoring of electroencephalography, electrooculography, electromyography (chin and legs), electrocardiography, oronasal airflow, thoracic and abdominal belts, pulse oximetry to measure oxygen saturation (SpO₂), snoring microphone, and body position sensor. The scoring was performed manually and was interpreted by two board-certified sleep physicians in accordance with previous guidelines [22], being that both physicians were blinded to the FeNO values. Data from PSG included total sleep time, sleep efficiency, sleep stages, rapid eye movement and sleep latencies, arousal index, apnea/hypopnea index (AHI), SpO₂ values (awake, mean, nadir, and
cumulative time with $\text{SpO}_2 < 90\%$), and oxygen desaturation index (ODI) with a threshold of 3%. Apneas were classified with a drop $\geq 90\%$ of baseline in airflow lasting at least 10 s [22]. Hypopneas were classified with a drop $\geq 30\%$ of pre-event during $\geq 10$ s associated with $\geq 3\%$ oxygen desaturation or an arousal [22]. Diagnosis of OSA was based on an AHI $\geq 5.0$/h, being its severity classified based on the AHI thresholds: $\geq 5.0$/h as any OSA, $\geq 15.0$/h as moderate/severe OSA, and $\geq 30.0$/h as severe OSA.

Statistical Analysis

Data analysis was conducted using a statistical software package (SPSS, version 21.0; Chicago, IL, USA). Results are presented as mean ± standard deviation for continuous variables and as number and percentage for categorical variables. Comparisons between groups were performed using the Chi-square test for dichotomous variables, Student’s $t$ test, and univariate analysis of variance (ANOVA) for continuous variables. Correlation was evaluated by Spearman rank correlation coefficient ($r$). At three AHI thresholds (5.0/h, 15.0/h, and 30.0/h), the predictive performance of FeNO was assessed by logistic regression tests and receiver operating characteristic (ROC) curves with area under the curve (AUC). An AUC > 0.7 was considered as clinically significant discrimination. Both AUC and odds ratio (OR) were reported with their respective 95% confidence intervals (CI).

Results

Of a total of 272 consecutive subjects referred for diagnostic PSG, 43 patients (15.8%) were subsequently excluded: 31 patients were using corticosteroids and/or had known respiratory disease and 12 patients were current smokers. Thus, a total of 229 adult patients—including 162 males (70.7%) and 67 females (29.3%)—were considered eligible for further analyses. No PSG needed to be repeated. Baseline and polysomnographic characteristics are shown in Table 1. Mean age was 43.7 ± 12.6 years, mean BMI was 31.1 ± 6.5 kg/m², and mean NC was 40.6 ± 4.5 cm. Hypertension and diabetes mellitus were present in 32.8% and 14.0% of the patients, respectively. As anticipated from the study design and recruitment of a referral cohort to a sleep-laboratory setting, we found a high frequency of any OSA (86.9%), moderate/severe OSA (62.4%), and severe OSA (39.7%). As expected, patients with diagnosis of any OSA, moderate/severe OSA, and severe OSA had a male predominance (73.9%, 76.2%, and 83.5%; respectively). There were no gender differences in FeNO values: 18.1 ± 14.1 ppb in females versus 20.5 ± 14.0 ppb in males; $p = 0.234$.

Mean ESS was 9.4 ± 4.5 points, being that 38.9% of the patients were sleepy. We observed a poor discrimination of ESS in predicting any OSA, moderate/severe OSA, and severe OSA: AUC: 0.537 (95% CI: 0.405–0.669; $p = 0.517$), AUC: 0.529 (95% CI: 0.451–0.606; $p = 0.466$), and AUC: 0.565 (95% CI: 0.490–0.640; $p = 0.097$); respectively. Conversely, No-Apnea model showed to be a useful tool for screening of any OSA, moderate/severe OSA and severe OSA: AUC: 0.786 (95% CI: 0.696–0.877; $p < 0.001$), AUC: 0.713 (95% CI: 0.644–0.782; $p < 0.001$), and AUC: 0.717 (95% CI: 0.650–0.784; $p < 0.001$); respectively.

Correlation

Table 2 shows the correlation between FeNO and some numeric parameters: all clinical and polysomnographic

---

**Table 1 Patients characteristics (n = 229)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical data</td>
<td></td>
</tr>
<tr>
<td>Male gender (%)</td>
<td>162 (70.7)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>43.7 ± 12.6</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.1 ± 6.5</td>
</tr>
<tr>
<td>NC (cm)</td>
<td>40.6 ± 4.5</td>
</tr>
<tr>
<td>Caucasian (%)</td>
<td>185 (80.8)</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>75 (32.8)</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>32 (14.0)</td>
</tr>
<tr>
<td>ESS, points</td>
<td>9.4 ± 4.5</td>
</tr>
<tr>
<td>No-Apnea, points</td>
<td>4.4 ± 2.5</td>
</tr>
<tr>
<td>FeNO (ppb)</td>
<td>19.8 ± 14.1</td>
</tr>
<tr>
<td>Polysomnographic data</td>
<td></td>
</tr>
<tr>
<td>Total sleep time (min)</td>
<td>339.3 ± 58.8</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>79.7 ± 13.2</td>
</tr>
<tr>
<td>Sleep latency (min)</td>
<td>39.1 ± 39.0</td>
</tr>
<tr>
<td>REM latency (min)</td>
<td>140.5 ± 71.1</td>
</tr>
<tr>
<td>Sleep stage NREM1 (%)</td>
<td>6.4 ± 5.0</td>
</tr>
<tr>
<td>Sleep stage NREM2 (%)</td>
<td>66.2 ± 10.4</td>
</tr>
<tr>
<td>Sleep stage NREM3 (%)</td>
<td>9.5 ± 8.1</td>
</tr>
<tr>
<td>Sleep stage REM (%)</td>
<td>17.5 ± 6.8</td>
</tr>
<tr>
<td>Arousal index (n/h)</td>
<td>31.0 ± 25.3</td>
</tr>
<tr>
<td>AHI (n/h)</td>
<td>30.1 ± 26.7</td>
</tr>
<tr>
<td>Awake $\text{SpO}_2$ (%)</td>
<td>94.6 ± 1.7</td>
</tr>
<tr>
<td>Mean $\text{SpO}_2$ (%)</td>
<td>92.8 ± 2.9</td>
</tr>
<tr>
<td>Nadir $\text{SpO}_2$ (%)</td>
<td>82.0 ± 8.8</td>
</tr>
<tr>
<td>ODI (n/h)</td>
<td>26.9 ± 25.9</td>
</tr>
<tr>
<td>$\text{SpO}_2 &lt; 90%$ (min)</td>
<td>27.0 ± 51.3</td>
</tr>
</tbody>
</table>

Numeric and categorical variables were presented as mean ± standard deviation and n (%), respectively

$BM$ body mass index, $NC$ neck circumference, $ESS$ Epworth Sleepiness Scale, $FeNO$ fraction of exhaled nitric oxide, $AHI$ Apnea/Hypopnea Index, $REM$ rapid eye movement, $\text{SpO}_2$ oxygen saturation, $ODI$ oxygen desaturation index at 3%
Predicting OSA with FeNO

Mean FeNO values were similar among subjects without OSA (AHI < 5.0/h) or with OSA (AHI ≥ 5.0/h): 16.9 ± 10.6 ppb versus 20.2 ± 14.5 ppb, p = 0.221; respectively. In addition, Fig. 2 shows FeNO measurements according to four AHI intervals: <5.0/h (without OSA), 5.0–14.9/h (mild OSA), 15.0–29.9/h (moderate OSA), and ≥30.0/h (severe OSA), illustrating that mean FeNO values were not statistically different across severity categories based on AHI (p value for trend = 0.392).

FeNO was not a relevant retainable parameter to predict any OSA, moderate/severe OSA, and severe OSA: OR 1.023 (95% CI: 0.986–1.062; p = 0.220); OR 1.012 (95% CI: 0.991–1.034; p = 0.251); and OR 0.999 (95% CI: 0.980–1.018; p = 0.931), respectively. Corroborating the findings described above, we also observed a poor discrimination of FeNO in predicting any OSA, moderate/severe OSA, and severe OSA (Fig. 3): AUC: 0.567 (95% CI: 0.464–0.670; p = 0.235), AUC: 0.541 (95% CI: 0.465–0.618; p = 0.295), and AUC: 0.535 (95% CI: 0.459–0.610; p = 0.376), respectively.

Discussion

In the present study, FeNO measurements emerge as a clearly not useful measurement when applied as a potential screening tool for OSA in patients with a high pre-test probability of SDB. In addition, our study indicated that FeNO values were not significantly different in those patients with or without OSA. Studies investigating the effect of OSA on FeNO measurements are inconsistent and with conflicting results [10–19, 23]. Similar to our findings, a study [19] with 129 consecutive patients, aged ≥ 16 years, showed no value in incorporating FeNO in the screening of OSA, considering that FeNO values were similar among individuals with or without SDB, and also whether SDB was defined by an AHI threshold of ≥ 5.0/h or ≥ 15.0/h. Similarly, there were no differences in FeNO concentrations in individuals with OSA (n = 24) and in healthy individuals (n = 7) [18]. A probable explanation for current findings could be that the inflammation that is generally present in patients with OSA may not be eosinophilic in nature. In addition, exclusion of patients with allergic rhinitis, asthma, and asthma–COPD overlap may also have contributed to the negative findings of FeNO as a screening approach for OSA.

Our study was conducted with FeNO measurements being always performed in the morning, aiming to minimize possible circadian-related variations, a feature that has been previously reported as a potential confounder [24]. Differences before and after the sleep periods [16] have led to the recommendation of standardizing the time of day when FeNO measurements are conducted. Moreover, it was also noted that establishment of reference values for FeNO is difficult, given the large number of frequently occurring factors that can influence this measurement [25]. For example, smoking, gender, age, weight, height, atopy, respiratory/nasal symptoms, use of steroids, and diet have all been implicated in the variance of FeNO.

A previous study [17] evaluated the changes of FeNO before and after sleep as function of BMI. FeNO levels in subjects without OSA as well as those with OSA were similar, but significant increases were detected in obese patients with OSA, suggesting that obesity is modifying factor and potentially enhances inflammation in the airways in patients with OSA [17]. Similarly, a study [11] with 43 individuals (18 obese patients with OSA, 15 obese patients without OSA, and 10 healthy subjects) showed that FeNO was significantly increased in OSA and in obese patients.
Lung

Fig. 1 Scatterplot of individual AHI values, nadir oxygen saturation (SpO₂), ODI at 3%, and cumulative time with SpO₂ < 90% plotted against the corresponding FeNO concentrations in 229 subjects. The Spearman rank correlation coefficients between FeNO and AHI, nadir SpO₂, ODI at 3%, and cumulative time with SpO₂ < 90% were all not significant ($p = 0.304, p = 0.218, p = 0.161, p = 0.481$; respectively)

Fig. 2 FeNO concentrations according to four AHI intervals: <5.0/h (without OSA), 5.0–14.9/h (mild OSA), 15.0–29.9/h (moderate OSA), and ≥30.0/h (severe OSA). Values of FeNO were reported as mean ± standard deviation. The mean FeNO values were not statistically different across categories de AHI ($p$ value for trend $= 0.392$) (23.1 ± 2.1 ppb and 17.9 ± 2.1 ppb) when compared to controls (7.2 ± 0.6 ppb), thereby supporting the hypothesis that obesity alone can alter the inflammatory status of the upper airway. Concurring findings [14] were reported in 60 patients reinforcing the concept that inflammation of the upper airways in obese patients with OSA and without OSA may be monitored by FeNO measurements.

Interestingly, in a series of 104 consecutive adult non-smokers (75 patients with OSA and 29 controls), FeNO values were elevated in OSA, were correlated with severity, and decreased after positive pressure therapy [12]. Furthermore, in patients with OSA, FeNO levels were significantly higher after sleep compared to measurements conducted at bedtime (19.0 ± 7.7 ppb vs. 13.4 ± 6.5 ppb), while there were no significant overnight changes in patients without OSA. In addition, FeNO levels declined after 1–3 months of CPAP
therapy (11.7 ± 4.4 ppb, \( p < 0.001 \)). Nearly identical results were reported in a smaller series of 26 patients [26]. Thus, based on aforementioned studies, it would appear that CPAP therapy yields clinical benefits by reducing upper airway inflammation and oxidative stress in OSA patients.

Similar to our findings, some studies have shown no usefulness of ESS as a screening tool for OSA [27–30]. Conversely, a practical and extremely simple 2-item model, No-Apnea [21], showed adequate discriminatory ability for detection of OSA in a clinical referral cohort. In the original derivation cohort, the AUCs for screening for any OSA, moderate/severe OSA, and severe OSA were: 0.784 (95% CI: 0.761–0.808); 0.758 (95% CI: 0.737–0.777), and 0.754 (95% CI: 0.733–0.776); respectively, and the validation cohort essentially confirmed such findings, thereby establishing its reproducibility, and its non-inferiority performance when compared to two previously validated tools (STOP-Bang questionnaire [31] and NoSAS score [32], containing eight and five parameters, respectively) [21].

**Limitations and Strengths**

Our study had some limitations: patient selection occurred in a single sleep laboratory; therefore the possibility of selection bias is plausible and generalizability of the findings may be limited. In most sleep laboratories, patients referred for PSG are often suspected of suffering from OSA and therefore represent a high pre-test probability cohort. In addition, all patients included had FeNO measured at the same time (only in the morning): this certainly does not exclude daily variations, it only minimizes circadian or time of day confounders as possible measurement bias. According to some previous studies [12, 13, 17], which have shown that FeNO measurements are greater immediately upon awakening than at night, especially in patients with OSA versus patients without OSA, we chose to measure FeNO in the next morning after PSG, immediately upon waking up. However, several points are also worthy of mention. Our patients were consecutively and prospectively recruited and the sample size was larger than other similar studies that have previously evaluated FeNO. All patients underwent in-lab PSG with the same diagnostic criteria proposed by American Academy of Sleep Medicine [22], regardless of whether their clinical symptoms included respiratory complaints or not. Moreover, all polysomnographic studies were of sufficient quality for inclusion in the analyses.

**Conclusions**

In a contextual setting of clinical referral cohort to a sleep laboratory, FeNO measurements do not show evidence of sufficient discriminatory ability to warrant the inclusion of this measurement for the screening of OSA in adult patients.

**Compliance with Ethical Standards**

**Conflict of interest** The authors declare that they have no competing interests.

**References**


